Table 5.
Types of drugs investigated in the top-cited papers on anti-PD1/PDL1 immunotherapy.
| Drug types | Number of papers | Total number of citations | Average number of citations (per paper) | Average number of citations per year (per paper) | |
|---|---|---|---|---|---|
| Nivolumab | 42 | 71,606 | 1,704.9 | 295.4 | |
| Pembrolizumab | 34 | 43,352 | 1,275.1 | 273.6 | |
| Atezolizumab | 12 | 13,863 | 1,155.3 | 308.6 | |
| Durvalumab | 6 | 4,686 | 781 | 209.8 | |
| Avelumab | 3 | 1,968 | 656 | 177.5 | |
| Pidilizumab | 1 | 405 | 405 | 50.6 | |
| Lambrolizumab | 1 | 2,446 | 2,446 | 287.8 | |
| Cemiplimab | 1 | 514 | 514 | 146.9 | |
PD1, programmed cell death 1; PDL1, programmed cell death 1 ligand 1.